RSCM
VRTX icon

Rock Springs Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Rock Springs Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-9,000
Closed -$2.45M – 162
2020
Q3 		$2.45M Sell
9,000
-116,000
-93% -$32M 0.06% 139
2020
Q2 		$36.3M Hold
125,000
– – 1% 39
2020
Q1 		$29.7M Sell
125,000
-78,000
-38% -$17.9M 1.23% 32
2019
Q4 		$44.4M Hold
203,000
– – 1.4% 16
2019
Q3 		$34.4M Hold
203,000
– – 1.37% 21
2019
Q2 		$37.2M Hold
203,000
– – 1.35% 19
2019
Q1 		$37.3M Hold
203,000
– – 1.44% 15
2018
Q4 		$33.6M Buy
203,000
+7,000
+4% +$1.21M 1.59% 14
2018
Q3 		$37.8M Buy
196,000
+5,500
+3% +$979K 1.37% 15
2018
Q2 		$32.4M Buy
190,500
+9,500
+5% +$1.47M 1.25% 21
2018
Q1 		$29.5M Buy
181,000
+9,750
+6% +$1.59M 1.26% 22
2017
Q4 		$25.7M Buy
171,250
+19,750
+13% +$2.92M 1.16% 26
2017
Q3 		$23M Buy
151,500
+22,500
+17% +$3.39M 1.06% 26
2017
Q2 		$16.6M Buy
129,000
+38,500
+43% +$4.63M 0.84% 44
2017
Q1 		$9.9M Buy
90,500
+750
+0.8% +$66K 0.57% 58
2016
Q4 		$6.61M Hold
89,750
– – 0.44% 65
2016
Q3 		$7.83M Buy
89,750
+4,250
+5% +$402K 0.49% 58
2016
Q2 		$7.36M Buy
85,500
+1,600
+2% +$138K 0.54% 57
2016
Q1 		$6.67M Buy
83,900
+11,150
+15% +$1.01M 0.56% 57
2015
Q4 		$9.15M Buy
72,750
+500
+0.7% +$60.4K 0.69% 51
2015
Q3 		$7.52M Buy
72,250
+4,250
+6% +$546K 0.61% 60
2015
Q2 		$8.4M Hold
68,000
– – 0.61% 60
2015
Q1 		$8.02M Buy
68,000
+5,000
+8% +$599K 0.75% 46
2014
Q4 		$7.48M Buy
63,000
+5,500
+10% +$619K 0.88% 41
2014
Q3 		$6.46M Buy
57,500
+11,250
+24% +$1.07M 1% 33
2014
Q2 		$4.38M Buy
46,250
+30,250
+189% +$2.12M 0.79% 47
2014
Q1 		$1.13M Sell
16,000
-4,000
-20% -$317K 0.26% 70
2013
Q4 		$1.49M Buy
+20,000
New +$1.39M 0.53% 52

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Rock Springs Capital Management's VRTX Position: Q4 2020 in Review

Rock Springs Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2020, closing a stake of 9,000 shares — an estimated $2.45M sold.

Rock Springs Capital Management first reported a position in VRTX in Q4 2013 and held it in 28 quarters. The position peaked at $44.4M in Q4 2019. 971 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • Rock Springs Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Rock Springs Capital Management sold 9,000 Vertex Pharmaceuticals shares in Q4 2020, an estimated $2.45M.
  • Rock Springs Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2013 and held it in 28 quarters.
  • Rock Springs Capital Management's Vertex Pharmaceuticals position peaked at $44.4M in Q4 2019.
  • 971 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on Rock Springs Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.